V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007311 | 10005162 | null | null | Neo-adjuvant (N) | 2018-03-08 | 2018-03-08 | Pazopanib | N | N | 10531827 | METHOTREXATE INTRATHECAL |
| 10007312 | 10007581 | 1.74 | null | Adjuvant (A) | 2017-04-02 | 2017-06-05 | ECX | N | N | 10532112 | IRINOTECAN |
| 10007313 | 10008621 | 1.57 | null | Palliative (P) | 2016-04-25 | 2016-05-28 | Cetuximab + Oxaliplatin + MdG Maint | 2 | Y | 10532185 | LIPOSOMAL DOXORUBICIN |
| 10007314 | 10007582 | null | 65.6 | Disease modification (D) | 2016-05-11 | 2016-05-12 | IPM | N | N | 10532257 | CHOP |
| 10007315 | 10007582 | null | 84.2 | Disease modification (D) | 2017-01-20 | 2017-01-21 | HCX (Cape + Cisp + Tras) - Load | N | N | 10532257 | CISPLATIN + GEMCITABINE |
| 10007316 | 10007582 | 1.58 | 58.2 | Palliative (P) | 2017-08-16 | 2017-08-30 | Vinorelbine (oral) | N | N | 10532257 | VEDEX |
| 10007317 | 10005164 | 1.8 | 76.3 | Palliative (P) | 2017-09-18 | 2017-09-19 | IDELALISIB + RITUXIMAB | N | N | 10532623 | MELPHALAN |
| 10007318 | 10005165 | 1.63 | null | Curative (C) | 2018-06-09 | 2018-06-15 | Cisplatin + Etoposide po | 02 | N | 10532743 | CETUXIMAB |
| 10007319 | 10005166 | 1.75 | null | Curative (C) | null | 2018-02-20 | EOX | null | Y | 10532743 | OXALIPLATIN + RALTITREXED |
| 10007320 | 10005166 | null | 76.9 | Adjuvant (A) | null | 2017-02-12 | Bortezomib +/- Dexamethasone | N | N | 10532743 | IRINOTECAN |
| 10007321 | 10005168 | 0 | 74.7 | Curative (C) | 2016-12-29 | 2017-01-12 | IRINOTECAN + MDG + PANITUMUMAB | N | N | 10533229 | NIVOLUMAB |
| 10007322 | 10005169 | 0 | 84.6 | Disease modification (D) | 2015-06-15 | 2015-06-30 | Methotrexate intrathecal | N | N | 10533229 | EC |
| 10007323 | 10005170 | 1.64 | 80 | Adjuvant (A) | 2016-07-31 | 2016-08-19 | Pazopanib | N | N | 10533451 | NINTEDANIB |
| 10007324 | 10005171 | 1.71 | 80 | Adjuvant (A) | 2015-03-04 | 2015-04-01 | Capecitabine (21 day) + Irinotecan | 02 | N | 10533576 | BORTEZOMIB |
| 10007325 | 10005171 | 1.79 | 0 | Neo-adjuvant (N) | 2016-12-30 | 2018-02-01 | Methotrexate intrathecal | 02 | Y | 10533576 | METHOTREXATE INTRATHECAL |
| 10007326 | 10005171 | 1.64 | 108.1 | Palliative (P) | 2018-02-02 | 2018-03-21 | Bevacizumab+Carbo+Pacliaxel | 2 | null | 10533576 | ERLOTINIB |
| 10007327 | 10005172 | 1.75 | 69 | Palliative (P) | 2016-08-03 | 2016-10-09 | Capecitabine (14 day) + Irinotecan | 2 | N | 10534314 | MPV |
| 10007328 | 10005173 | 1.72 | 72 | Curative (C) | 2019-02-02 | 2019-02-07 | GDP | 02 | N | 10534329 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 10007329 | 10005174 | 1.69 | 62.8 | Adjuvant (A) | 2018-06-21 | 2018-07-03 | RUXOLITINIB | 2 | n | 10534514 | SPIRE TRIAL |
| 10007330 | 10005179 | 1.73 | 64.4 | Curative (C) | 2015-09-27 | 2015-09-27 | Carboplatin + Liposomal Doxorubicin | N | N | 10534561 | DA |
| 10007331 | 10005179 | 1.66 | 74.8 | Palliative (P) | 2018-11-25 | 2018-11-28 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | N | N | 10534561 | PCV |
| 10007332 | 10005180 | 0 | 71.7 | Adjuvant (A) | null | 2018-06-18 | EC | null | N | 10534701 | PANITUMUMAB |
| 10007333 | 10005182 | 1.8 | null | Disease modification (D) | 2018-03-28 | 2018-03-30 | Ipilimumab | 02 | N | 10534882 | CISPLATIN + GEMCITABINE |
| 10007334 | 10005183 | null | 91.8 | Curative (C) | 2016-10-20 | 2016-11-02 | PACLITAXEL + TRASTUZUMAB | 02 | N | 10534927 | METHOTREXATE HIGH DOSE |
| 10007335 | 10007589 | 1.77 | 75.9 | Adjuvant (A) | 2016-05-05 | 2016-05-06 | LOMUSTINE + PROCARBAZINE | 02 | N | 10535061 | INCA TRIAL |
| 10007336 | 10005184 | 1.69 | 83 | null | 2017-01-29 | 2017-03-20 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | Y | 10535352 | BORTEZOMIB |
| 10007337 | 10007590 | 1.6 | 57.5 | Palliative (P) | 2017-07-05 | 2017-07-09 | Cetuximab 14 day | 02 | N | 10535352 | EVEROLIMUS |
| 10007338 | 10005185 | 1.79 | 104.7 | Palliative (P) | 2016-06-28 | 2016-06-28 | Lomustine | 02 | N | 10535409 | EOX |
| 10007339 | 10005188 | 1.75 | 0 | null | 2017-06-27 | 2017-07-06 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 2 | N | 10535646 | ATG + BUSULFAN + FLUDARABINE |
| 10007340 | 10005189 | 0 | 0 | Disease modification (D) | 2018-02-10 | 2018-02-14 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | 10535646 | CETUXIMAB + OXALIPLATIN + MDG |
| 10007341 | 10005189 | 1.72 | 77.9 | Curative (C) | 2015-05-23 | 2015-05-30 | Pazopanib | 0 | N | 10535646 | R-EPOCH |
| 10007342 | 10005190 | null | null | Palliative (P) | 2018-12-12 | 2018-12-13 | AML 18 TRIAL | N | Y | 10536379 | VINORELBINE |
| 10007343 | 10005193 | 1.6 | 93 | Curative (C) | 2014-05-10 | 2014-05-10 | FEC | 2 | N | 10536442 | CAP + RT |
| 10007344 | 10005195 | null | 60.8 | Disease modification (D) | null | 2019-02-23 | NIVOLUMAB | N | Y | 10536543 | BUSULPHAN |
| 10007345 | 10005196 | 1.71 | 134 | null | 2016-12-22 | 2016-12-22 | BENDAMUSTINE | N | N | 10536600 | HYDROXYCARBAMIDE |
| 10007346 | 10007593 | 1.75 | null | Disease modification (D) | 2017-09-07 | 2018-11-14 | VINORELBINE | 02 | N | 10536766 | GEMCITABINE + OXALIPLATIN + RITUXIMAB |
| 10007347 | 10005200 | 1.83 | 53.1 | Curative (C) | 2015-04-27 | 2015-05-09 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | N | 10536813 | TOPOTECAN |
| 10007348 | 10005202 | 1.88 | 62.8 | Disease modification (D) | 2017-12-22 | 2017-12-26 | CHLORAMBUCIL + RITUXIMAB | N | null | 10536857 | RIALTO TRIAL |
| 10007349 | 10005202 | null | 73.1 | Palliative (P) | 2019-06-16 | 2019-06-30 | Cisplatin + Pemetrexed | N | Y | 10536857 | CETUXIMAB + IRINOTECAN + MDG |
| 10007350 | 10005204 | 1.67 | 102 | Palliative (P) | 2018-08-06 | 2018-08-08 | Cisplatin + Pemetrexed | N | N | 10537309 | IRINOTECAN |
| 10007351 | 10005205 | 1.58 | 91.2 | Palliative (P) | 2018-02-19 | 2018-02-19 | Capecitabine + Cisplatin + RT | N | N | 10537310 | SUNITINIB |
| 10007352 | 10005206 | 1.57 | 60.9 | Palliative (P) | 2015-08-26 | 2015-12-10 | Bortezomib +/- Dexamethasone | N | N | 10537524 | CHLORAMBUCIL |
| 10007353 | 10005207 | 1.64 | 70 | Palliative (P) | 2014-11-28 | 2014-12-12 | PROCAID TRIAL | N | N | 10537534 | CAPECITABINE + CISPLATIN + RT |
| 10007354 | 10005207 | 1.6 | null | Not known (9) | 2013-06-30 | 2013-07-28 | Cisplatin + Vinorelbine (IV) | N | N | 10537534 | VEDEX |
| 10007355 | 10007599 | null | 91.4 | Curative (C) | 2013-12-05 | 2013-12-10 | Cisplatin+Gemcitabine (gallbladder) | N | null | 10537747 | NIVOLUMAB |
| 10007356 | 10005210 | 1.77 | 66.9 | Palliative (P) | 2017-04-14 | 2017-04-14 | Cetuximab + Radiotherapy Load | N | Y | 10537747 | CAPECITABINE + CISPLATIN |
| 10007357 | 10005212 | 1.78 | 66.6 | Disease modification (D) | 2018-06-21 | 2018-06-21 | Hydroxycarbamide | 02 | Y | 10538612 | PROCARBAZINE |
| 10007358 | 10007602 | 1.77 | 94 | Palliative (P) | 2017-02-16 | 2017-02-17 | IMATINIB | null | null | 10538752 | CISPLATIN + VINORELBINE |
| 10007359 | 10005214 | 1.8 | 87.6 | Curative (C) | 2018-03-06 | 2018-03-26 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | 10538801 | ERLOTINIB |
| 10007360 | 10005215 | 1.58 | 68.4 | Palliative (P) | 2017-07-21 | 2017-07-30 | Bortezomib +/- Dexamethasone | N | N | 10538869 | CETUXIMAB |